

In the Claims

This listing of claims will replace all prior versions and listings of claims in this application.

1-43. (cancelled).

44 (currently amended). A peptide or polypeptide obtained from the armadillo domain of human β -catenin polypeptide which ~~affects~~ inhibits the interaction of human β -catenin polypeptide and a transcription factor or tumor suppressor protein, wherein said peptide or polypeptide is selected from a the group consisting of peptides or polypeptides having comprising the sequences shown in SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.

45 (currently amended). A peptide or polypeptide obtained from the armadillo domain of human β -catenin polypeptide which ~~affects~~ inhibits the interaction of human β -catenin polypeptide and a transcription factor or tumor suppressor protein, wherein said peptide or polypeptide is selected from a the group consisting of peptides or polypeptides having comprising the sequences shown in SEQ ID NO: 6 having a mutation in Phe in position 253 30 or a mutation in His in position 260 37 or both; SEQ ID NO: 7 having a mutation in Arg in position 274 2 or a mutation in Lys in position 292 27 or both; SEQ ID NO: 8 having a mutation in Trp in position 338 32 or a mutation in Arg in position 342 36 or a mutation in Lys in position 345 39 or any combination of mutations thereof; SEQ ID NO: 9 having a mutation in Lys in position 354 5 or mutation in TRP in position 383 34 or a mutation in Arg in position 386 37 or any combination of mutations thereof; SEQ ID NO: 10 having a mutation in Lys in position 394 4; and SEQ ID NO: 11 having a mutation in Lys in position 435 6 or a mutation in Arg in position 457 28 or a mutation in Arg in position 469 40 or a mutation in His in position 470 41 or any combination of mutations thereof, wherein said mutation replaces the indicated amino acid with a ~~different~~ an aliphatic amino acid.

3

Docket No. BB-112T
Serial No. 09/641,104

46 (cancel).

47 (currently amended). The mutant according to claim 43 or 44, wherein said mutation replaces the indicated amino acid with ~~an aliphatic amino acid such as~~ alanine, valine, leucine or isoleucine.

48 (previously presented). The mutant according to claim 45, wherein said mutation replaces the indicated amino acid with alanine.

49 (cancel).

50 (previously presented). The peptide of claim 47, wherein the effect is to inhibit the interaction of β -catenin and said transcription factor or tumor suppressor protein selected from the group of lymphoid enhancer-binding factor-1 (LEF-1), T cell transcription factor-1 (TCF-1), adenomatous polyposis coli 15 (APC 15) ~~LEF-1, TCF-1, APC 15,~~ conductin, E-cadherin and 20 amino acid repeats of APC.

JASH-RESP\BPD\BB-112-~~doc.doc~~DNB/la